FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Altamira Therapeutics Ltd. Stock AnalysisComprehensive stock analysis for Altamira Therapeutics Ltd. (EARS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisEARS
EARS
Altamira Therapeutics Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
EARS
Home🔹Stocks🔹Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

EARS•NASDAQ

Altamira Therapeutics Ltd.

EARS•NASDAQ
Market cap
$4.21M
Sentiment

Your view on EARS

Mkt Cap
$4.21M
Sentiment
Your view
EARS
Altamira Therapeutics Ltd.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
EARS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Altamira Therapeutics Ltd.

Industry
Biotechnology
Sector
Healthcare
CEO
Thomas Meyer
Headquarters
CH
Industry
Biotechnology
Sector
Healthcare
CEO
Thomas Meyer
Headquarters
CH
Description

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News